Centerpoint Energy Inc
$48.38B- Market cap
- $25.95B
- Debt
- +$22.98B
- Cash
- −$548.00M
Capital structure 53% equity / 47% debt · EV / Revenue 5.17x · EV / EBITDA 19.33x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CNP stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at CNP's multiple
Needs EPS (TTM) is negative, CNP P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CNP FY 2025 (ended Dec 31, 2025) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 53% equity / 47% debt · EV / Revenue 5.17x · EV / EBITDA 19.33x
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
CNP carries the larger enterprise value at $48.38B against $334.64M; ZNTL trades on the lower EV / Revenue multiple (4.96x vs 5.17x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CENTERPOINT ENERGY INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
2.06x
0.24x
Net debt / EBITDA
Leverage against operating earnings
8.96x
-0.29x
Cash and equivalents
Liquid reserves on the balance sheet
$548.00M
$33.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEXTERA ENERGY INC
CNP vs NEE
DOMINION ENERGY, INC
CNP vs D
SOUTHERN CO
CNP vs SO
CONSOLIDATED EDISON INC
CNP vs ED
Arcus Biosciences, Inc.
CNP vs RCUS
Repare Therapeutics Inc.
CNP vs RPTX
IDEAYA Biosciences, Inc.
CNP vs IDYA
Mersana Therapeutics, Inc.
CNP vs MRSN
EXELIXIS, INC.
CNP vs EXEL
$22.98B
$82.57M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.